Compare Charles River Laboratories Intl. Inc (CRL) vs Nvidia Corp (NVDA) Price & Performance

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

NVIDIA (NVDA) trades at $208.23, up 2.31% on the day, with a bullish technical signal from moving averages. The stock shows exceptional fundamental strength with revenue soaring to $130.5B in 2025 and net income margins reaching 62.97%. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $1.87 surpassing the $1.76 estimate. The company maintains robust profitability metrics including 74.15% gross margins and 114.29% ROE, though valuation ratios remain elevated with P/E at 32.43 and P/S at 20.44.

The outlook remains positive with strong analyst consensus (75.32% buy ratings) and a $325.86 price target suggesting significant upside. Key opportunities include continued AI chip dominance and expanding market opportunities, while risks include increased competition, potential peak AI infrastructure spending, and elevated valuation multiples that could limit near-term growth. The stock's proximity to its 52-week high warrants monitoring of momentum sustainability.